Trial
JUPITER: rosuvastatin results in older participants
Research Observatory
Evidence Update
Current evidence
JUPITER compared rosuvastatin 20 mg daily with placebo. This exploratory report concerns 5,695 participants aged 70 or older without cardiovascular disease, with LDL cholesterol below 130 mg/dL and elevated hsCRP (at least 2 mg/L).Cardiovascular event rates were 1.22 with rosuvastatin and 1.99 with placebo per 100 person-years. The estimate for death from any cause remained uncertain. Participants had a selected risk profile. The abstract does not establish a separate result for everyone aged 80 or older, a personal time to benefit, or a complete harms assessment.This study-specific finding does not establish general clinical efficacy or longer life.
What changed
Study findings and context:In JUPITER participants aged >=70 with elevated hsCRP and low-to-average LDL, an exploratory analysis found fewer vascular events with rosuvastatin, while the all-cause mortality estimate remained uncertain.
What did not change
This exploratory analysis did not establish a survival benefit or an effect for all older adults. It is a subgroup of an existing trial, not a new trial.
Why it matters
Keeps a favorable cardiovascular finding separate from an unproven survival benefit.
Main limitation
Post-hoc age cutoff and selected inflammatory-risk phenotype. Mortality CI includes the null; no proof of no effect or of survival extension. Absolute rates are per 100 person-years, unlike ASPREE rates per 1000. No qualified personal time-to-benefit rule, separate >=80 estimate or full safety appraisal. Access qualification: Official indexed author abstract only; full methods and supplements unreviewed.
Next proof
Use the linked original reports to check the findings. Full methods, tables and supplements were not reviewed in this evidence package. Broader clinical questions require separate evidence review.
Study findings and exact evidence
Rosuvastatin 20 mg daily (JUPITER regimen)
Rosuvastatin: selected older subgroup, uncertain survival benefit
ACCEPT_AS_CONTEXT
What was tested? Rosuvastatin 20 mg daily was compared with placebo for a first cardiovascular event. This report examines older participants in the JUPITER trial.
Who participated? The analysis included 5,695 participants aged 70 or older, without cardiovascular disease, with LDL cholesterol below 130 mg/dL and raised hsCRP, an inflammation marker. The age cutoff was chosen after trial completion.
Findings Cardiovascular event rates were 1.22 with rosuvastatin and 1.99 with placebo per 100 person-years. The estimate for death from any cause remained uncertain.
What was not demonstrated? This exploratory analysis did not establish a survival benefit or an effect for all older adults. It is a subgroup of an existing trial, not a new trial.
Harms and limitations Participants had a selected risk profile. The abstract does not establish a separate result for everyone aged 80 or older, a personal time to benefit, or a complete harms assessment.
In JUPITER participants aged >=70 with elevated hsCRP and low-to-average LDL, an exploratory analysis found fewer vascular events with rosuvastatin, while the all-cause mortality estimate remained uncertain.
Exact accepted support, hierarchy and limitations
exact accepted proposition
In JUPITER participants aged >=70 with elevated hsCRP and low-to-average LDL, an exploratory analysis found fewer vascular events with rosuvastatin, while the all-cause mortality estimate remained uncertain.
exact numeric support
[{"confidence_interval": [0.46, 0.82], "confidence_level": 0.95, "denominator_note": "Separate randomized arm Ns not given in indexed abstract; not inferred.", "effect_scale": "hazard_ratio", "endpoint": "First cardiovascular event", "estimate": 0.61, "p_value": "<0.001", "population_denominator": 5695, "rate_comparator": 1.99, "rate_intervention": 1.22, "rate_unit": "per 100 person-years"}, {"confidence_interval": [0.62, 1.04], "confidence_level": 0.95, "effect_scale": "hazard_ratio", "endpoint": "All-cause mortality", "estimate": 0.8, "p_value": 0.09, "population_denominator": 5695, "rate_comparator": 2.04, "rate_intervention": 1.63, "rate_unit": "per 100 person-years"}]exact original limitations
Post-hoc age cutoff and selected inflammatory-risk phenotype. Mortality CI includes the null; no proof of no effect or of survival extension. Absolute rates are per 100 person-years, unlike ASPREE rates per 1000. No qualified personal time-to-benefit rule, separate >=80 estimate or full safety appraisal. Access qualification: Official indexed author abstract only; full methods and supplements unreviewed.
exposure and comparator
Rosuvastatin 20 mg daily Comparator: Placebo within parent randomized trial
follow up
Person-time rates in subgroup abstract; exact subgroup follow-up horizon not qualified from inspected abstract
interpretation
Hazard ratios compare event hazards during follow-up; they are not individual probabilities or cumulative risk differences. Confidence intervals express uncertainty. Person-years add participants’ follow-up time.
outcome hierarchy
Parent primary first cardiovascular event composite evaluated in an exploratory older subgroup; age cutoff chosen after trial completion. All-cause mortality is distinct.
population
5695 of 17802 randomized JUPITER participants were >=70, without CVD, with LDL <130 mg/dL and hsCRP >=2 mg/L. Species: Homo sapiens.
Summary
JUPITER compared rosuvastatin 20 mg daily with placebo. This exploratory report concerns 5,695 participants aged 70 or older without cardiovascular disease, with LDL cholesterol below 130 mg/dL and elevated hsCRP (at least 2 mg/L).Cardiovascular event rates were 1.22 with rosuvastatin and 1.99 with placebo per 100 person-years. The estimate for death from any cause remained uncertain. Participants had a selected risk profile. The abstract does not establish a separate result for everyone aged 80 or older, a personal time to benefit, or a complete harms assessment.This study-specific finding does not establish general clinical efficacy or longer life.
Intelligence Take
Keeps a favorable cardiovascular finding separate from an unproven survival benefit.
Limitations
Post-hoc age cutoff and selected inflammatory-risk phenotype. Mortality CI includes the null; no proof of no effect or of survival extension. Absolute rates are per 100 person-years, unlike ASPREE rates per 1000. No qualified personal time-to-benefit rule, separate >=80 estimate or full safety appraisal. Access qualification: Official indexed author abstract only; full methods and supplements unreviewed.